Relapsed or Refractory AML and Other Hematologic Malignancies Clinical Trials in Kanazawa

Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.